Skip to main content
Laurus Labs Limited logo

Laurus Labs Limited — Investor Relations & Filings

Ticker · LAURUSLABS ISIN · INE947Q01028 LEI · 335800S8HO8QRYP3VQ26 BSE.NS Manufacturing
Open in API
Filings indexed 705 across all filing types
Latest filing 2023-10-20 Investor Presentation
Country IN India
Listing BSE.NS LAURUSLABS

About Laurus Labs Limited

https://www.lauruslabs.com/

Laurus Labs Limited is a research-driven organization focused on the development and manufacturing of active pharmaceutical ingredients (APIs), finished dosage forms (FDF), and specialized synthesis services. The company operates across several key therapeutic areas, including anti-retroviral (ARV), oncology, cardiovascular, and anti-diabetic treatments. Through its contract development and manufacturing organization (CDMO) division, it provides integrated drug development solutions to global partners. The company also maintains a biotechnology segment dedicated to recombinant products. Leveraging advanced research and development capabilities alongside large-scale manufacturing infrastructure, the firm emphasizes process chemistry innovation and cost-efficient production to serve diverse global healthcare markets.

Recent filings

Filing Released Lang Actions
Investor Presentation
Investor Presentation Classification · 100% confidence The document is a detailed presentation dated October 20, 2023, titled 'Q2 & H1 FY 2024 Investor Presentation' for Laurus Labs Limited. It includes comprehensive financial results for the quarter and half year ended September 30, 2023, business updates, strategic initiatives, operational excellence, capex projects, breakthrough innovations, R&D focus, regulatory approvals, and outlook. The content is structured as a presentation aimed at investors and analysts, with slides covering corporate overview, financial overview, business review, and outlook. It is not a brief announcement or a certification letter, but a full investor presentation document. Therefore, the appropriate classification is 'Investor Presentation' (IP).
2023-10-20 English
Outcome of Board Meeting
Regulatory Filings
2023-10-20 English
Financial Result Updates
Regulatory Filings
2023-10-20 English
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a short disclosure letter addressed to stock exchanges (BSE and NSE) regarding the update on acquisition of shares of Laurus Bio Private Limited. It references a previous disclosure about signing a Share Purchase Agreement (SPA) and provides an update on the completion of part of the acquisition. The content is an announcement of a transaction related to share acquisition, specifically a secondary purchase of equity shares from promoters and employees. The document length is only 1564 characters, indicating it is a brief announcement rather than a detailed report. There are no financial statements, earnings data, or management discussion. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share acquisitions.
2023-10-16 English
Updates
Regulatory Filings Classification · 95% confidence The document is a formal announcement addressed to stock exchanges (BSE and NSE) under Regulation 30, which pertains to disclosure requirements for listed companies. The content announces the approval of a new CAR-T cell therapy product by an associate company, ImmunoACT, from the Central Drugs Standard Control Organization (CDSCO). It includes a press release detailing the product, clinical trial results, and strategic significance. There are no financial statements, management discussion and analysis, or detailed financial data. The document is primarily a regulatory disclosure about a significant business development (product approval) rather than a financial report or earnings release. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance disclosure that does not fit other specific categories.
2023-10-13 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a press release dated October 13, 2023, announcing an upcoming earnings conference call for Q2 & 1H FY 2024 results scheduled on October 20, 2023. It includes details about the call, dial-in numbers, and a brief company overview. There are no actual financial results or detailed financial statements included in the text. The document serves as an invitation and notification for the earnings call rather than the earnings release itself. According to the classification rules, such announcements of conference calls are best classified as Call Transcript (CT) only if the full transcript is provided, which is not the case here. Since this is an announcement of the call, it does not fit the Earnings Release (ER) category either. The document is essentially a Regulatory Filing (RNS) as it is a general regulatory announcement informing the market about the upcoming event without substantive financial data or transcript content.
2023-10-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.